rosiglitazone has been researched along with simvastatin in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (48.39) | 29.6817 |
| 2010's | 15 (48.39) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Akiyama, TE; Berger, JP; Chang, CH; Doebber, TW; Einstein, M; Liu, K; Liu, W; McCann, ME; Meinke, PT; Wood, HB | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kipnes, MS; Lewin, AJ; Maccubbin, DL; Meneghini, LF; Mitchel, YB; Perevozskaya, IT; Plotkin, DJ; Shah, S; Tobert, JA | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Kiselevich, A; London, D; Magen, E; Priluk, R; Viskoper, RJ; Volchek, L; Yosefy, C | 1 |
| Han, KH; Hong, KH; Kim, JB; Kim, JJ; Ko, J; Pak, YK; Park, SW; Ryu, J | 1 |
| Laverty, R; Ledingham, JM | 1 |
| Ball, SG; Mughal, RS; O'Regan, DJ; Porter, KE; Turner, NA; Warburton, P | 1 |
| Eng, C; Planchon, SM; Teresi, RE; Waite, KA | 1 |
| Eisendle, K; Fritsch, P; Linder, D; Philipp, W; Piza, H; Ratzinger, G; Schmuth, M; Zelger, B | 1 |
| Chen, K; Liao, W; Pan, L; Wen, J; Xu, H; Zhou, M | 1 |
| Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A | 1 |
| Bläuer, M; Murtola, TJ; Pennanen, P; Syvälä, H; Tammela, TL; Ylikomi, T | 1 |
| Akinci, B; Bayraktar, F; Comlekci, A; Demir, T; Ozcan, MA; Yener, S; Yesil, S; Yuksel, F | 1 |
| Bowsman, M; Chen, M; Cordover, D; Fordstrom, P; Hale, C; Helmering, J; Kaufman, SA; Lloyd, DJ; Véniant, MM; Wang, M; Zhou, M | 1 |
| Becker, L; Gharib, SA; Heinecke, JW; Irwin, AD; Oram, JF; Vaisar, T; Wijsman, E | 1 |
| Drazen, JM; Wood, AJ | 1 |
| Li, N; Ramji, DP; Salter, RC | 1 |
| Bakris, G; de Guzman, E; Lazich, I; Oliva, R; Patel, A; Sarafidis, P | 1 |
| Brenna, JT; Kim, AJ; Kothapalli, KS; Park, WJ; Reardon, HT; Zhang, J | 1 |
| Dong, P; Fan, G; Fordjour, PA; Gao, H; Gong, B; Li, L; Zhu, Y | 1 |
| Guo, Y; Hao, H; Huo, J; Ji, X; Liu, Q; Nie, B; Wu, D; Zhao, E | 1 |
1 review(s) available for rosiglitazone and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for rosiglitazone and simvastatin
| Article | Year |
|---|---|
Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Male; Middle Aged; Pioglitazone; Rosiglitazone; Simvastatin; Thiazolidinediones | 2004 |
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
Topics: Administration, Oral; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, LDL; Cilazapril; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Evoked Potentials; Female; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Kidney; Male; Rosiglitazone; Simvastatin; Skin Physiological Phenomena; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Ultrasonography; Vasodilation | 2004 |
Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Pressure; Carboxypeptidase B2; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Simvastatin; Thiazolidinediones | 2009 |
Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C-Reactive Protein; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Isoprostanes; Lipids; Male; Malondialdehyde; Metabolic Syndrome; Middle Aged; Oxidative Stress; Rosiglitazone; Simvastatin; Thiazolidinediones | 2012 |
26 other study(ies) available for rosiglitazone and simvastatin
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Drug Discovery; Dyslipidemias; Female; Humans; Indoles; Male; Mice; PPAR gamma; Rats; Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrroles; Rosiglitazone; Simvastatin; Thiazolidinediones; United States; United States Food and Drug Administration | 2004 |
HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo.
Topics: Anilides; Animals; Aorta; Cells, Cultured; Chemokine CCL2; Chemotaxis, Leukocyte; Depression, Chemical; Diet, Atherogenic; Down-Regulation; Drug Evaluation, Preclinical; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Monocytes; Polyisoprenyl Phosphates; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptors, CCR2; Receptors, Chemokine; RNA, Messenger; Rosiglitazone; Sesquiterpenes; Simvastatin; Thiazolidinediones | 2005 |
Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Basilar Artery; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Mesenteric Arteries; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Wistar; Rosiglitazone; Simvastatin; Tetrazoles; Thiazolidinediones; Tunica Media; Valine; Valsartan | 2005 |
Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones.
Topics: Analysis of Variance; Antibodies, Monoclonal; Cells, Cultured; Chromans; Coronary Disease; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1alpha; Interleukin-1beta; Interleukin-6; Interleukins; Myocytes, Cardiac; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Simvastatin; Stimulation, Chemical; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha | 2007 |
Regulation of the PTEN promoter by statins and SREBP.
Topics: Cell Line; Electrophoretic Mobility Shift Assay; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation; Genes, Reporter; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; PPAR gamma; Pravastatin; Promoter Regions, Genetic; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Simvastatin; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Up-Regulation | 2008 |
Inflammation and lipid accumulation in xanthoma disseminatum: Therapeutic considerations.
Topics: Adult; Histiocytosis, Non-Langerhans-Cell; Humans; Inflammation; Lipid Metabolism; Male; Pyrazines; Rosiglitazone; Simvastatin; Thiazolidinediones | 2008 |
Rosiglitazone promotes atherosclerotic plaque stability in fat-fed ApoE-knockout mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Dietary Fats; Granulocyte-Macrophage Colony-Stimulating Factor; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Rosiglitazone; Simvastatin; Thiazolidinediones | 2008 |
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2008 |
Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Division; Cell Line, Transformed; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Epithelial Cells; Growth Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Prostate; Prostatic Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones | 2009 |
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Animals; Atherosclerosis; Blood Glucose; Body Composition; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Dyslipidemias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Mice; Mice, Knockout; Rosiglitazone; Simvastatin; Thiazolidinediones; Triglycerides | 2009 |
A macrophage sterol-responsive network linked to atherogenesis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Foam Cells; Gene Expression Regulation; Hypoglycemic Agents; Hypolipidemic Agents; Macrophages; Male; Mice; Mice, Inbred C57BL; Proteins; Receptors, LDL; Rosiglitazone; Simvastatin; Sterols; Thiazolidinediones | 2010 |
Don't mess with the DSMB.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hypoglycemic Agents; Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones; United States | 2010 |
Molecular mechanisms underlying the inhibition of IFN-γ-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs.
Topics: Blotting, Western; Butyrates; Cell Line; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Electrophoretic Mobility Shift Assay; Humans; Hydrocarbons, Fluorinated; Interferon-gamma; Liver X Receptors; Macrophages; Orphan Nuclear Receptors; Peroxisome Proliferator-Activated Receptors; Phenylurea Compounds; Rosiglitazone; Simvastatin; STAT1 Transcription Factor; Sulfonamides; Thiazolidinediones; Transfection | 2011 |
Insertion-deletions in a FADS2 intron 1 conserved regulatory locus control expression of fatty acid desaturases 1 and 2 and modulate response to simvastatin.
Topics: Base Sequence; Benzoates; Benzylamines; Binding Sites; Cells, Cultured; Conserved Sequence; Delta-5 Fatty Acid Desaturase; Fatty Acid Desaturases; Gene Expression; Gene Expression Regulation; Gene Frequency; Haplotypes; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; INDEL Mutation; Introns; Linkage Disequilibrium; Liver X Receptors; Locus Control Region; Multigene Family; Oligonucleotide Array Sequence Analysis; Orphan Nuclear Receptors; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Response Elements; Rosiglitazone; Sequence Analysis, DNA; Simvastatin; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones | 2012 |
Danshensu Promotes Cholesterol Efflux in RAW264.7 Macrophages.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; CD36 Antigens; Cholesterol; Foam Cells; Gene Expression Regulation; Genetic Markers; Lactates; Lipoproteins, LDL; Macrophages; Mice; PPAR gamma; RAW 264.7 Cells; Rosiglitazone; Simvastatin; Thiazolidinediones | 2016 |
Simvastatin inhibits the adipogenesis of bone marrow‑derived mesenchymal stem cells through the downregulation of chemerin/CMKLR1 signaling.
Topics: Adipogenesis; Animals; Bone Marrow Cells; Cells, Cultured; Chemokines; Female; Mesenchymal Stem Cells; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptors, Chemokine; Rosiglitazone; Signal Transduction; Simvastatin | 2020 |